Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230340 | 1.00 | TSHR (0.55) | TSHRRXFP1MAPTCHRM3CHRM2 | |
| SCHEMBL227333 | 0.94 | CHRM3 (0.53) | TSHRRXFP1MAPTCHRM3CHRM2 | |
| SCHEMBL227334 | 0.94 | CHRM3 (0.53) | TSHRRXFP1MAPTCHRM3CHRM2 | |
| SCHEMBL227273 | 0.90 | CHRM3 (0.54) | CHRM3CHRM2CHRM1 | |
| SCHEMBL227457 | 0.90 | CHRM3 (0.50) | TSHRRXFP1MAPTCHRM3CHRM2 | |
| SCHEMBL227272 | 0.90 | CHRM3 (0.54) | CHRM3CHRM2CHRM1 | |
| SCHEMBL227458 | 0.90 | CHRM3 (0.50) | TSHRRXFP1MAPTCHRM3CHRM2 | |
| SCHEMBL227121 | 0.89 | CHRM3 (0.49) | TSHRRXFP1MAPTCHRM3CHRM2 | |
| SCHEMBL227120 | 0.89 | CHRM3 (0.49) | TSHRRXFP1MAPTCHRM3CHRM2 | |
| SCHEMBL227236 | 0.88 | ALDH1A1 (0.54) | TSHRRXFP1MAPTCHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313404-B1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2012-03-28 | — | — | EP | disclosed |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| US-8039483-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | disclosed |
| EP-2313404-A1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | TSHR 1262/4885RXFP1 424/4885MAPT 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.